GURUFOCUS.COM » STOCK LIST » USA » NYSE » Johnson & Johnson (NYSE:JNJ) » Definitions » Intrinsic Value: Projected FCF
Switch to:

Johnson & Johnson Intrinsic Value: Projected FCF

: $95.20 (As of Today)
View and export this data going back to 1944. Start your Free Trial

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2022-08-13), Johnson & Johnson's Intrinsic Value: Projected FCF is $95.20. The stock price of Johnson & Johnson is $165.30. Therefore, Johnson & Johnson's Price-to-Intrinsic-Value-Projected-FCF of today is 1.7.

The historical rank and industry rank for Johnson & Johnson's Intrinsic Value: Projected FCF or its related term are showing as below:

JNJ' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.87   Med: 1.82   Max: 5.8
Current: 1.74

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Johnson & Johnson was 5.80. The lowest was 0.87. And the median was 1.82.

JNJ's Price-to-Projected-FCF is ranked worse than
52.73% of 586 companies
in the Drug Manufacturers industry
Industry Median: 1.66 vs JNJ: 1.74

Johnson & Johnson Intrinsic Value: Projected FCF Historical Data

The historical data trend for Johnson & Johnson's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Intrinsic Value: Projected FCF
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74.43 74.00 77.97 83.25 92.15

Johnson & Johnson Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Intrinsic Value: Projected FCF Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 89.27 91.56 92.15 92.34 95.20

Competitive Comparison

For the Drug Manufacturers - General subindustry, Johnson & Johnson's Intrinsic Value: Projected FCF, along with its competitors' market caps and Intrinsic Value: Projected FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Johnson & Johnson Intrinsic Value: Projected FCF Distribution

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's Intrinsic Value: Projected FCF distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's Intrinsic Value: Projected FCF falls into.



Johnson & Johnson Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Johnson & Johnson's Free Cash Flow(6 year avg) = $18,920.64.

Johnson & Johnson's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Jun22)*0.8)/Shares Outstanding (Diluted Average)
=(10.195616806174*18920.64+76357*0.8)/2667.900
=95.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Johnson & Johnson  (NYSE:JNJ) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Johnson & Johnson's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=165.30/95.20341660766
=1.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Johnson & Johnson Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Johnson & Johnson Business Description

Johnson & Johnson logo
Address
One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total sales are generated in the United States.
Executives
Adamczyk Darius director 855 S. MINT STREET CHARLOTTE NC 28202
Hait William officer: See Remarks ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Mammen Mathai officer: EVP, Pharm, R&D THERAVANCE,INC. 901 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080
Broadhurst Vanessa officer: EVP, Global Corp Aff. ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Swanson James D. officer: EVP, Chief Information Officer ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
West Nadja director 1915 REXFORD ROAD CHARLOTTE NC 28211
Decker Robert J officer: Controller, CAO ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Joly Hubert director C/O BEST BUY CO, INC. 7601 PENN AVENUE SOUTH RICHFIELD MN 55423
Weinberger Mark A director METLIFE, INC. 200 PARK AVENUE NEW YORK NY 10166
Hewson Marillyn A director C/O CARPENTER TECHNOLOGY CORPORATION PO BOX 14662 READING PA 19612-4662
Mongon Thibaut officer: Exec VP, WW Chair, Consumer JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Wengel Kathryn E officer: EVP, Chief GSC Officer JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Wolk Joseph J officer: Exec VP, CFO JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Mcevoy Ashley officer: EVP, WW Chair, Medical Devices JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Taubert Jennifer L officer: EVP, WW Chair, Pharmaceuticals JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933

Johnson & Johnson Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)